Veranova CEO, Mike Riley, discusses the transition from chemicals to CDMO

Mike Riley, Veranova’s CEO, spoke to Newsweek and Investment Reports to discuss the transition from chemicals to specialized CDMO.

“The spin-out from Johnson Matthey provided us with increased focus on our core business, maintaining our legacy in building strong technical capabilities and infrastructure. The transition to a CDMO also required us to cultivate a partnership-focused culture essential for working with pharmaceutical companies. As a result, we have been able to invest in unique capabilities that are crucial for our success in this competitive sector.

“Since the acquisition, Veranova has indeed become more focused on strategic investments in capabilities and infrastructure aimed at enhancing our technical and operational strengths. As an independent entity backed by robust private equity, we’re positioned to respond dynamically to the evolving demands of our clients and the market.”

Investment Reports logo

Veranova is your next great decision

Discover new ways to advance your science with Veranova.

Contact us